Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Rritual Superfoods Ready to Launch Amazon Store in USAAtai Life Sciences Is Setting The Stage For The Largest IPO The Psychedelics Sector Has Seen To DateEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available fMajor U.S. States Are Taking A Serious Look At Decriminalizing Psychedelic Compounds For The Treatment Of Mental IllnessMAPS Canada Is Leading The Global Charge To Commercialize Psychedelic TherapiesBetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of DirectorsMindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic MedicineTryp Therapeutics Partners with Alcami for Proprietary FormulationsHAVN Life Secures Production & Supply Agreement to Expand Retail Product OfferingsCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery MechanismsNuminus Wellness Is One Of The Shining Stars Of The Psychedelic SectorPsychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream MediaMAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern MedicineRritual Superfoods Initiates Canadian Retail Growth Strategy Signing with Ultimate Sales CanadaNuminus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for SevTryp Therapeutics Partners with Clinlogix for Clinical Trial SupportTryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail Growth

Psychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream Media

May 21, 2021 • 6:27 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

2021 has been a banner year for the psychedelic therapy market and we believe the industry is in the early innings of a major growth cycle. 

With interest growing for data from biotech and non-profit research firms that are conducting Food and Drug Administration (FDA) clinical trials on psychedelic therapies. The clinical studies are focused primarily on mental health illnesses and we are favorable on how these breakthrough therapies can help patients that are impacted by debilitating mental health disorders. 

The current state of the psychedelic therapy market looks similar to the cannabis industry in 2016. We expect the psychedelic industry to benefit from positive clinical data that is being published by biotech and non-profit research firms. 

In 2016, GW Pharmaceuticals plc (GWPH) reported positive Phase 3 clinical data and the development served as a catalyst for the entire cannabis sector. The cannabis biotech firm was recently acquired by Jazz Pharmaceuticals plc (JAZZ) and we expect to see similar transactions in the psychedelic industry once these firms start to report positive clinical data.

The COVID pandemic has only stressed the need for better treatments from mental illnesses. Two of the indications that are being studied by psychedelic therapy firms are major depressive disorder (MDD) and post-traumatic-stress-disorder (PTSD). We believe these indications have massive total addressable markets (TAMs) and are favorable on the potential value that can be created for firms that successfully develop a treatment for them.

Earlier this month, Nature published the results from a Phase 3 clinical trial on MDMA as a treatment for PTSD. The study was conducted by the Multidisciplinary Association of Psychedelic Studies (MAPS) and the data that was reported was positive. According to the study, 67% of participants receiving MDMA therapy reported a reduction in symptoms after 18 weeks and three sessions.

Patients who received the therapy reported a substantial decrease in the number nightmares they have. Less than a third of the control group had similar outcomes and the data shows that adding MDMA to the treatment regimen helps patients overcome PTSD faster.

Over the next year, we expect to receive clinical data from companies like MAPS, Cybin, and ATAI Life Sciences. We believe the industry has substantial growth prospects and will monitor how it benefits from positive clinical trial data. 

If you are interested in learning about psychedelic therapy companies that are in advanced clinical trials, please send an email to with the subject “Biotech Psychedelic Companies” to be added to our distribution list.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.